Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. [electronic resource]
Producer: 20060912Description: 3831-7 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antineoplastic Agents -- adverse effects
- Canada
- Carcinoma, Non-Small-Cell Lung -- complications
- Cough -- etiology
- Double-Blind Method
- Dyspnea -- etiology
- Erlotinib Hydrochloride
- Female
- Humans
- Lung Neoplasms -- complications
- Male
- Middle Aged
- Odds Ratio
- Pain -- etiology
- Protein Kinase Inhibitors -- therapeutic use
- Quality of Life
- Quinazolines -- adverse effects
- Surveys and Questionnaires
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.